Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment

Overview

Journal Front Pharmacol

Date 2022 May 26

PMID 35614940

Authors

Xianbo Wu

Yihua Xu

Qi Liang

Xinwei Yang

Jianli Huang

Jie Wang

Hong Zhang

Jianyou Shi

Affiliations

Soon will be listed here.

Abstract

The PI3K-Akt-mTOR pathway is a viable target for cancer treatment and can be used to treat various malignant tumours, including follicular lymphoma and breast cancer. Both enzymes, PI3K and mTOR, are critical in this pathway. Hence, in recent years, an array of inhibitors targeting these two targets have been studied, showing dual PI3K/mTOR inhibition compared with single targeting small molecule inhibitors. Inhibitors not only inhibit cell proliferation but also promote cell apoptosis. These inhibitors show high potency and little drug resistance even at low doses, suggesting that PI3K/mTOR inhibitors are promising cancer drugs. Herein, we summarised the recent research of PI3K/mTOR dual inhibitors-for example, structure-activity relationship, pharmacokinetics, and clinical practice, and briefly commented on them. https://clinicaltrials.gov.

Citing Articles

The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.

Molefi T, Mabonga L, Hull R, Mwazha A, Sebitloane M, Dlamini Z Cells. 2025; 14(5).

PMID: 40072110 PMC: 11898822. DOI: 10.3390/cells14050382.

Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches.

Singh G, Rohit , Kumar P, Aran K Med Oncol. 2025; 42(4):97.

PMID: 40064710 DOI: 10.1007/s12032-025-02652-1.

All-trans retinoic acid enhances anti-proliferative effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in triple negative breast cancer.

Ayvaz S, Bolat Z Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40042556 DOI: 10.1007/s00210-025-03981-8.

Decoding Osteosarcoma's Lactylation Gene Expression: Insights Into Prognosis, Immune Dynamics, and Treatment.

Peng C, You C, Cao S, Cheng L, Ren J, Cao J Anal Cell Pathol (Amst). 2025; 2025:6517238.

PMID: 40026531 PMC: 11870760. DOI: 10.1155/ancp/6517238.

PI3K/AKT/mTOR Targeting in Colorectal Cancer Radiotherapy: A Systematic Review.

Mousavikia S, Darvish L, Firouzjaei A, Toossi M, Azimian H J Gastrointest Cancer. 2025; 56(1):52.

PMID: 39849185 DOI: 10.1007/s12029-024-01160-1.

References

Sutherlin D, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J . Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem. 2011; 54(21):7579-87. DOI: 10.1021/jm2009327. View

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

Baiz D, Pozzato G, Dapas B, Farra R, Scaggiante B, Grassi M . Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie. 2008; 91(3):373-82. DOI: 10.1016/j.biochi.2008.10.015. View

Yuan J, Mehta P, Yin M, Sun S, Zou A, Chen J . PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011; 10(11):2189-99. DOI: 10.1158/1535-7163.MCT-11-0185. View

Kuger S, Flentje M, Djuzenova C . Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Radiat Oncol. 2015; 10:214. PMC: 4619315. DOI: 10.1186/s13014-015-0514-5. View

Rehan M . Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches. PLoS One. 2019; 14(6):e0219180. PMC: 6597235. DOI: 10.1371/journal.pone.0219180. View

Thorpe L, Yuzugullu H, Zhao J . PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2014; 15(1):7-24. PMC: 4384662. DOI: 10.1038/nrc3860. View

Xu C, Zhao L, Yue P, Fang G, Tao H, Owonikoko T . Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther. 2011; 12(6):549-55. PMC: 3218593. DOI: 10.4161/cbt.12.6.16397. View

Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung S . SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006; 127(1):125-37. DOI: 10.1016/j.cell.2006.08.033. View

10.

Papadopoulos K, Tabernero J, Markman B, Patnaik A, Tolcher A, Baselga J . Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2014; 20(9):2445-56. DOI: 10.1158/1078-0432.CCR-13-2403. View

11.

Hart S, Novotny-Diermayr V, Goh K, Williams M, Tan Y, Ong L . VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther. 2012; 12(2):151-61. PMC: 3588144. DOI: 10.1158/1535-7163.MCT-12-0466. View

12.

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K . MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010; 9(7):1956-67. DOI: 10.1158/1535-7163.MCT-09-1012. View

13.

Mustafa N, Lee J, Adina Nee H, Bi C, Chung T, Hart S . VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim. Oncotarget. 2017; 8(60):101847-101864. PMC: 5731918. DOI: 10.18632/oncotarget.21988. View

14.

Yu P, Laird A, Du X, Wu J, Won K, Yamaguchi K . Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014; 13(5):1078-91. DOI: 10.1158/1535-7163.MCT-13-0709. View

15.

Shiota C, Woo J, Lindner J, Shelton K, Magnuson M . Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell. 2006; 11(4):583-9. DOI: 10.1016/j.devcel.2006.08.013. View

16.

Dienstmann R, Rodon J, Serra V, Tabernero J . Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014; 13(5):1021-31. DOI: 10.1158/1535-7163.MCT-13-0639. View

17.

Wang W, Liao L, Wang Y, Li H, Suo Z, Long K . Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent. Cancer Biol Ther. 2018; 19(11):1015-1022. PMC: 6301802. DOI: 10.1080/15384047.2018.1470733. View

18.

Salphati L, Heffron T, Alicke B, Nishimura M, Barck K, Carano R . Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Clin Cancer Res. 2012; 18(22):6239-48. DOI: 10.1158/1078-0432.CCR-12-0720. View

19.

Xu M, Xu L, Wang Y, Dai G, Xue B, Liu Y . BRD4 inhibition sensitizes renal cell carcinoma cells to the PI3K/mTOR dual inhibitor VS-5584. Aging (Albany NY). 2020; 12(19):19147-19158. PMC: 7732329. DOI: 10.18632/aging.103723. View

20.

Wu T, Guo Q, Chen Z, Wang L, Du Y, Chen R . Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors. Eur J Med Chem. 2020; 204:112637. DOI: 10.1016/j.ejmech.2020.112637. View